Literature DB >> 18258839

Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype.

Edward G Stopa1, Parag Butala, Stephen Salloway, Conrad E Johanson, Liliana Gonzalez, Rosemarie Tavares, Virginia Hovanesian, Christine M Hulette, Michael P Vitek, Ronald A Cohen.   

Abstract

BACKGROUND AND
PURPOSE: We examined the associations among the vascular beta-amyloid levels, smooth muscle actin, wall thickness, and lumen diameter to achieve greater understanding of the arteriolar changes that accompany Alzheimer disease (AD).
METHODS: Post-mortem pathology brain specimens from 76 patients with AD and 19 non-AD age control subjects were studied. We analyzed arterioles of the frontal cortex (Brodmann area 10) by immunohistochemistry and morphometry, and derived measures of vascular beta-amyloid level, smooth muscle actin (SMA) volume, and arteriolar wall thickness and lumen diameter. APOE genotype was determined for each case.
RESULTS: Overall, there was a striking reciprocal relationship between arteriolar beta-amyloid volume and smooth muscle actin (P<0.0001). In addition, there was a strong positive association between progressively accumulating vascular beta-amyloid and augmentations in both wall thickness (P<0.0001) and lumen width (P<0.0001). In comparison with non-AD control subjects, smooth muscle actin was decreased in patients clinically diagnosed with AD and was reduced >10-fold in cases with AD pathology (Braak I to VI) compared with those lacking AD neuropathology. Significantly altered composition and structure of cortical vessels in pre-Braak stages corroborated our hypothesis that arterioles are devastated early in the AD pathological process. Smooth muscle actin, arteriolar wall thickness, and luminal diameter did not vary with Braak stage severity (P>0.05), indicating that substantial arteriolar damage may precede at least some of the interstitial plaques and neuronal tangles. Moreover, the structural and biochemical arteriolar abnormalities did not vary as a function of APOE genotype (P>0.05).
CONCLUSIONS: We postulate that in elderly patients, the continually progressing beta-amyloid-associated angiopathy, at the arteriolar level, harms the contractile apparatus and cerebral blood flow autoregulation, thereby making the downstream capillaries vulnerable to damage. Collectively, our observations lend further support to the idea that microvascular damage has a role, perhaps relatively early, in the onset of major AD pathology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258839     DOI: 10.1161/STROKEAHA.107.493429

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  21 in total

1.  Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Brian R Ott; Ronald A Cohen; Assawin Gongvatana; Ozioma C Okonkwo; Conrad E Johanson; Edward G Stopa; John E Donahue; Gerald D Silverberg
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy.

Authors:  Natalia N Nalivaeva; Anthony J Turner
Journal:  Br J Pharmacol       Date:  2019-03-11       Impact factor: 8.739

Review 3.  The vascular contribution to Alzheimer's disease.

Authors:  Robin Altman; John C Rutledge
Journal:  Clin Sci (Lond)       Date:  2010-08-05       Impact factor: 6.124

4.  High-definition characterization of cerebral β-amyloid angiopathy in Alzheimer's disease.

Authors:  Virawudh Soontornniyomkij; Cecilia Choi; Justine Pomakian; Harry V Vinters
Journal:  Hum Pathol       Date:  2010-08-04       Impact factor: 3.466

5.  Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study.

Authors:  Melita Salkovic-Petrisic; Jelena Osmanovic-Barilar; Martina K Brückner; Siegfried Hoyer; Thomas Arendt; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2011-04-30       Impact factor: 3.575

6.  Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease.

Authors:  Laura D Baker; Laura L Frank; Karen Foster-Schubert; Pattie S Green; Charles W Wilkinson; Anne McTiernan; Brenna A Cholerton; Stephen R Plymate; Mark A Fishel; G Stennis Watson; Glen E Duncan; Pankaj D Mehta; Suzanne Craft
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 7.  Beta-amyloid, blood vessels, and brain function.

Authors:  Eric E Smith; Steven M Greenberg
Journal:  Stroke       Date:  2009-05-14       Impact factor: 7.914

8.  Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice.

Authors:  Monica Garcia-Alloza; Claudia Prada; Carli Lattarulo; Sara Fine; Laura A Borrelli; Rebecca Betensky; Steven M Greenberg; Matthew P Frosch; Brian J Bacskai
Journal:  J Neurochem       Date:  2009-04-08       Impact factor: 5.372

Review 9.  The role of APOE in cerebrovascular dysfunction.

Authors:  Leon M Tai; Riya Thomas; Felecia M Marottoli; Kevin P Koster; Takahisa Kanekiyo; Alan W J Morris; Guojun Bu
Journal:  Acta Neuropathol       Date:  2016-02-16       Impact factor: 17.088

10.  Brain mural cell loss in the parietal cortex in Alzheimer's disease correlates with cognitive decline and TDP-43 pathology.

Authors:  P Bourassa; C Tremblay; J A Schneider; D A Bennett; F Calon
Journal:  Neuropathol Appl Neurobiol       Date:  2020-02-11       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.